Equities

Inari Medical Inc

Inari Medical Inc

Actions
  • Price (EUR)48.00
  • Today's Change0.00 / 0.00%
  • Shares traded40.00
  • 1 Year change-2.44%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Inari Medical Inc grew revenues 28.73% from 383.47m to 493.63m while net income improved from a loss of 29.27m to a smaller loss of 1.64m.
Gross margin86.82%
Net profit margin-13.68%
Operating margin-10.88%
Return on assets-12.61%
Return on equity-17.72%
Return on investment-15.24%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Inari Medical Inc fell by 21.01m. However, the company earned 35.93m from its operations for a Cash Flow Margin of 7.28%. In addition the company generated 1.17m cash from financing while 58.02m was spent on investing.
Cash flow per share-1.10
Price/Cash flow per share--
Book value per share7.44
Tangible book value per share1.33
More ▼

Balance sheet in USDView more

Inari Medical Inc uses little or no debt in its capital structure.
Current ratio1.77
Quick ratio1.40
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.